Our Broad and Disruptive Platform

We are delivering a new class of RNA therapeutics – Antibody Oligonucleotide Conjugates (AOCs™). AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. We have demonstrated preclinical proof of concept for AOCs in multiple tissues and recently demonstrated the first-ever successful targeted delivery of RNA into muscle in humans. We are working to broaden the reach of AOCs beyond skeletal muscle to target other tissues and cell types through both internal discovery efforts and key partnerships.

Our Advancing and Expanding Pipeline

Avidity’s proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Our advancing and expanding pipeline has three programs in clinical development. AOC 1001* is designed to treat people with myotonic dystrophy type 1 (DM1) and is in Phase 1/2 development with the recently completed MARINA™ and ongoing MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD.

*In Sept. 2022, Avidity announced that the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on new participant enrollment in the Phase 1/2 MARINA™ clinical trial of AOC 1001 in adults with DM1. All participants enrolled at the conclusion of the MARINA study were eligible to roll over into the MARINA-OLE™ trial where they will continue to receive AOC 1001 as planned. Avidity continues to work to resolve the partial clinical hold on new participant enrollment as swiftly as possible.

Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Beyond our clinical programs for muscle diseases, we have expanded our research and development efforts to include additional tissues and cell types such as cardiac tissue and immune cells. We are driven to accelerate our research to tackle unmet needs and better serve patients and their families.

Our Agile and Diverse Company

Our commitment to rigorous and innovative science is matched only by our passion to see patients’ lives changed. We consistently challenge ourselves to Be AVID – Agile, Visionary, Integrated and Diverse.

We continue to build a diverse team with experience in rare disease and RNA therapies. Our team members bring expertise in research, development and commercial execution. We are focused on cultivating the right team to not only grow the company, but also to reflect the communities we serve. We are dedicated to employing and retaining a diverse and inclusive workforce at all levels of the organization to ensure that different backgrounds and perspectives are being heard and acted upon, and our employees feel understood, accepted and valued.